Do you want to read an article? Please log in or register.
Growth differentiation factor 15 is a cancer cell-induced mitokine that primes thyroid cancer cells for invasiveness
Thyroid
Related content
COMMENTED
Thyroid
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
Lancet Diabetes Endocrinol.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A
doi: 10.1016/S2213-
Thyroid
ISTHMUS TOPOGRAPHY IS A RISK FACTOR FOR PERSISTENT DISEASE IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
Eur J Endocrinol
Campennì A, Ruggeri RM, Siracusa M, Giacoppo G, La Torre F, Saccomanno A, Alibrandi A, Dionigi G, Tuccari G, Baldari S, Giovanella L
doi: 10.1530/EJE-21-0328
Type 1 Diabetes
Age, ATA risk group and response to therapy are prognostic factors in children with differentiated thyroid cancer
J Clin Endocrinol Metab
Redlich A, Luster M, Lorenz K, Lessel L, Rohrer TR, Schmid KW, Frühwald MC, Vorwerk P, Kuhlen M
doi: 10.1210/clinem/dgab622
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin
Diabetes Care.
Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, Raman K, McQueen M, Lee S, Haenel H, Steinberg GR; ORIGIN Investigators
doi: 10.2337/dc16-1682
Thyroid
Higher TSH is not associated with thyroid cancer risk in the presence of thyroid autoimmunity
J Clin Endocrinol Metab.
Paparodis RD, Bantouna D, Karvounis E, Imam S, Jaume JC
doi: 10.1210/clinem/dgaa237.
RECOMMENDED
Thyroid
Screening for differentiated thyroid cancer in selected populations
★ 1
Recommended by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Lamartina L, Grani G, Durante C, Filetti S, Cooper DS
doi: 10.1016/S2213-8587(19)30324-9.
Thyroid
Predictive impact of metastatic lymph node burden on distant metastasis across papillary thyroid cancer variants
Thyroid
Ho AS, Luu M, Shafqat I, Mallen-St Clair J, Chen MM, Chen Y, Jain M, Ali N, Patio C, Filarski C, Lin DC, Bankston H, Braunstein G, Sacks W, Zumsteg ZS
doi: 10.1089/thy.2021.0131
COMMENTED
Thyroid
Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Thyroid
Yansong L, Yang H, Ding Y, Cheng Y, Shi F, Tan J, Deng Z, Chen Z, Wang R, Ji Q, Huang R, Li L
doi: 10.1089/thy.2020.0235
Thyroid
Blood polyphenol concentrations and differentiated thyroid carcinoma in women from the European Prospective Investigation into Cancer and Nutrition (EPIC) study
Am J Clin Nutr.
Zamora-Ros R, Lujan-Barroso L, Achaintre D, Franceschi S, Kyrø C, Overvad K, Tjønneland A, Truong T, Lecuyer L, Boutron-Ruault MC, Katzke V, Johnson TS, Schulze MB, Trichopoulou A, Peppa E, La Vechia C, Masala G, Pala V, Panico S, Tumino R, Ricceri F, Skeie G, Quirós JR, Rodriguez-Barranco M, Amiano P, Chirlaque MD, Ardanaz E, Almquist M, Hennings J, Vermeulen R, Wareham NJ, Tong TYN, Aune D, Byrnes G, Weiderpass E, Scalbert A, Rinaldi S, Agudo A
doi: 10.1093/ajcn/nqaa277.